logo-loader
viewVentriPoint Diagnostics Ltd.

Ventripoint showcases its latest VMS+3.0 cardio-monitoring system at American College of Cardiology's 68th Annual conference

VMS+3.0 is Ventripoint's newest version of its machine, which revolutionizes the way doctors treat heart patients as it gives accurate and rapid volumetric information on all four chambers of the heart

heart in hand
The Toronto company seized the opportunity to showcase the latest advances in its technology at the ACC’s Annual Scientific Session & Expo

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) said Tuesday that it staged a successful hands-on demonstration of its next-generation VMS+3.0 system at the American College of Cardiology’s 68th Annual Scientific Session & Expo in New Orleans over the weekend (March 16-March 18).

Not yet available for sale, the VMS+3.0 system is Ventripoint’s latest version of its machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.

READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).

Ventripoint's most up-to-date 3.0 system uses sensor technology, which allows for patients to move during the imaging portion of the examination, and it is compact and portable enough that it can be set up within minutes.

The Toronto company seized the opportunity to showcase the latest advances in its technology at the ACC’s Annual Scientific Session & Expo, which was attended by nearly 20,000 cardiologists.

The VMS+3.0 system is for investigational use only.

READ: Ventripoint Diagnostics reports progress for latest VMS +3.0 heart monitoring system

Ventripoint has developed a suite of applications to monitor heart disease. Its VMS+ system is the first AI tool for measuring the function of the entire heart using ultrasound.

Ventripoint shares closed at C$0.175 in Canadian trade on Monday.

Contact Ellen Kelleher at [email protected]

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.075 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $5.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 20/2/20

2 min read